We attempted to contact still-living FUSION spouses and offspring who participated in FUSION study visits between 1994 and 1998, individuals who had participated in the population-based Savitaipale Prospective Diabetes Study, the FINRISK 2007 survey, the Dose Responses to Exercise Training (DR's EXTRA) study and the Metabolic Syndrome in Men (METSIM) study. Additional subjects were recruited by newspaper advertisements.
Item
We attempted to contact still-living FUSION spouses and offspring who participated in FUSION study visits between 1994 and 1998, individuals who had participated in the population-based Savitaipale Prospective Diabetes Study, the FINRISK 2007 survey, the Dose Responses to Exercise Training (DR's EXTRA) study and the Metabolic Syndrome in Men (METSIM) study. Additional subjects were recruited by newspaper advertisements.
boolean
C2706094 (UMLS CUI [1,1])
C0947630 (UMLS CUI [1,2])
C4520849 (UMLS CUI [1,3])
C0162409 (UMLS CUI [1,4])
C0680063 (UMLS CUI [1,5])
C1512346 (UMLS CUI [1,6])
C1554109 (UMLS CUI [1,7])
C1709709 (UMLS CUI [1,8])
C4284887 (UMLS CUI [1,9])
C4279936 (UMLS CUI [1,10])
C0524620 (UMLS CUI [1,11])
C1524062 (UMLS CUI [2,1])
C0080105 (UMLS CUI [2,2])
C2949735 (UMLS CUI [2,3])
C0949214 (UMLS CUI [2,4])
C0027989 (UMLS CUI [2,5])
We excluded individuals: (1) with drug treatment for diabetes, (2) with diseases that might be expected to confound the analyses (for example, cancer, skeletal muscle diseases, acute or chronic inflammatory diseases), (3) with diseases that increase hemorrhage risk during biopsy (for example, von Willebrand's disease, hemophilia, severe liver diseases), (4) taking medications that need to be taken daily and increase hemorrhage risk in the biopsies including warfarin (patients on acetosalicylic acid were instructed to stop for 7 days prior to biopsy), (5) taking medications that could confound the analyses (for example, oral corticosteroids, other anti-inflammatory drugs such as 5-ASA, infliximab or methotrexate), and (6) of age <18 years.
Item
We excluded individuals: (1) with drug treatment for diabetes, (2) with diseases that might be expected to confound the analyses (for example, cancer, skeletal muscle diseases, acute or chronic inflammatory diseases), (3) with diseases that increase hemorrhage risk during biopsy (for example, von Willebrand's disease, hemophilia, severe liver diseases), (4) taking medications that need to be taken daily and increase hemorrhage risk in the biopsies including warfarin (patients on acetosalicylic acid were instructed to stop for 7 days prior to biopsy), (5) taking medications that could confound the analyses (for example, oral corticosteroids, other anti-inflammatory drugs such as 5-ASA, infliximab or methotrexate), and (6) of age <18 years.
boolean
C0680251 (UMLS CUI [1,1])
C0013216 (UMLS CUI [1,2])
C0011849 (UMLS CUI [1,3])
C0680251 (UMLS CUI [2,1])
C1517001 (UMLS CUI [2,2])
C4759729 (UMLS CUI [2,3])
C0006826 (UMLS CUI [2,4])
C0026848 (UMLS CUI [2,5])
C1290884 (UMLS CUI [2,6])
C1290886 (UMLS CUI [2,7])
C0680251 (UMLS CUI [3,1])
C0012634 (UMLS CUI [3,2])
C4039184 (UMLS CUI [3,3])
C0042974 (UMLS CUI [3,4])
C1096116 (UMLS CUI [3,5])
C5707743 (UMLS CUI [3,6])
C0680251 (UMLS CUI [4,1])
C0332173 (UMLS CUI [4,2])
C1290952 (UMLS CUI [4,3])
C4039184 (UMLS CUI [4,4])
C0043031 (UMLS CUI [4,5])
C0680251 (UMLS CUI [5,1])
C4759729 (UMLS CUI [5,2])
C0149783 (UMLS CUI [5,3])
C0442027 (UMLS CUI [5,4])
C0003209 (UMLS CUI [5,5])
C0666743 (UMLS CUI [5,6])
C0025677 (UMLS CUI [5,7])
C0680251 (UMLS CUI [6,1])
C0001779 (UMLS CUI [6,2])